Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GMNN | O75496 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.53 |
| ▸ | THPO | P40225 | 1/20 | 0.53 |
| ▸ | MTOR | P42345 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | HBB | P68871 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | HINT1 | P49773 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2101706 | 1.00 | GMNN (0.53) | GMNNALDH1A1LMNATP53NFKB1 | |
| SCHEMBL2101707 | 1.00 | GMNN (0.53) | GMNNALDH1A1LMNATP53NFKB1 | |
| SCHEMBL2101230 | 0.92 | GMNN (0.52) | GMNNALDH1A1LMNATP53NFKB1 | |
| SCHEMBL11794069 | 0.87 | GMNN (0.51) | GMNNALDH1A1LMNATP53NFKB1 | |
| SCHEMBL7684283 | 0.86 | L3MBTL1 (0.59) | LMNAMTORL3MBTL1 | |
| Elacytarabine SCHEMBL12137632 | 0.86 | L3MBTL1 (0.59) | LMNAMTORL3MBTL1 | |
| Elacytarabine SCHEMBL15140172 | 0.86 | L3MBTL1 (0.59) | LMNAMTORL3MBTL1 | |
| SCHEMBL7913995 | 0.84 | GMNN (0.57) | GMNNALDH1A1LMNATP53NFKB1 | |
| SCHEMBL7236374 | 0.82 | EHMT1 (0.63) | — | |
| SCHEMBL9046105 | 0.80 | L3MBTL1 (0.65) | LMNAMTORL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250000903-A1 | EXPANSION PROCESSES AND AGENTS FOR TUMOR INFILTRATING LYMPHOCYTES | IOVANCE BIOTHERAPEUTICS, INC. | 2025-01-02 | — | — | US | disclosed |
| EP-4404969-A1 | EXPANSION PROCESSES AND AGENTS FOR TUMOR INFILTRATING LYMPHOCYTES | Iovance Biotherapeutics, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| US-20230310479-A1 | LOW DOSE ADJUVANT EPIGENETIC CANCER THERAPY | UNIV JOHNS HOPKINS (US) | 2023-10-05 | — | — | US | disclosed |
| WO-2023049862-A1 | EXPANSION PROCESSES AND AGENTS FOR TUMOR INFILTRATING LYMPHOCYTES | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2023-03-30 | — | — | WO | disclosed |
| WO-2021081481-A1 | LOW DOSE ADJUVANT EPIGENETIC CANCER THERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-04-29 | — | — | WO | disclosed |
| US-10071112-B2 | Vitamin E-nucleoside prodrugs | EPIGENETICS PHARMA LLC (US) | 2018-09-11 | — | — | US | disclosed |
| US-20170298088-A1 | Vitamin E-Nucleoside Prodrugs | EPIGENETICS PHARMA LLC | 2017-10-19 | — | — | US | disclosed |
| EP-3204004-A1 | VITAMIN E-NUCLEOSIDE PRODRUGS | Epigenetics Pharma LLC (US) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016057825-A1 | VITAMIN E-NUCLEOSIDE PRODRUGS | EPIGENETICS PHARMA LLC (US) | 2016-04-14 | — | — | WO | disclosed |
| US-8158605-B2 | Azacytidine analogues and uses thereof | MOUNT SINAI SCHOOL OF MEDICINE (US) | 2012-04-17 | — | — | US | disclosed |
| EP-2197274-A1 | AZACYTIDINE ANALOGUES AND USES THEREOF | Mount Sinai School of Medicine (US) | 2010-06-23 | — | — | EP | disclosed |
| US-20090209482-A1 | AZACYTIDINE ANALOGUES AND USES THEREOF | MOUNT SINAI SCHOOL OF MEDICINE (US) | 2009-08-20 | — | — | US | disclosed |
| WO-2009042766-A9 | AZACYTIDINE ANALOGUES AND USES THEREOF | SINAI SCHOOL MEDICINE (US) | 2009-05-28 | — | — | WO | disclosed |
| WO-2009042766-A1 | AZACYTIDINE ANALOGUES AND USES THEREOF | MOUNT SINAI SCHOOL OF MEDICINE (US) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209482-A1 | AZACYTIDINE ANALOGUES AND USES THEREOF | TET2, TET3, AZI2 | GMNN 1694/4885ALDH1A1 526/4885LMNA 2457/4885 |
| US-10071112-B2 | Vitamin E-nucleoside prodrugs | NME2, NME1, TTPA | GMNN 2170/4885ALDH1A1 856/4885LMNA 924/4885 |
| US-20250000903-A1 | EXPANSION PROCESSES AND AGENTS FOR TUMOR INFILTRATING LYMPHOCYTES | NFATC1, MKI67, ICOS | GMNN 1972/4885ALDH1A1 2235/4885LMNA 3174/4885 |
| US-20170298088-A1 | Vitamin E-Nucleoside Prodrugs | NME2, NME1, TTPA | GMNN 2222/4885ALDH1A1 880/4885LMNA 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.